Retardation of angiographic progression of coronary artery disease by nifedipine

P, Lichtlen; Rafflenbeul, W.; Hecker, Hartmut; Jost, Stefan; Hugenholtz, Paul G.; Deckers, Jaap W.

doi:10.1016/0140-6736(90)91121-p

Cited by 572 publications

(71 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…46 The ability of CR nifedipine to inhibit MDMP generation provides additional evidence for the antiatherosclerotic action of this drug. 47,48 However, further studies are required to elucidate the mechanism by which hypoadiponectinaemia is improved by CR nifedipine. In conclusion, CR nifedipine directly or indirectly improved platelet activation markers, microparticles and adiponectin levels in hypertensive patients with diabetes.…”

Section: Discussionmentioning

confidence: 99%

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

et al. 2006

View full text Add to dashboard Cite

Nifedipine, a dihydropyridine calcium antagonist, improves endothelial function in patients with hypercholesterolaemia by enhancing nitric oxide (NO) activity, and increases endothelial NO bioavailability by antioxidant mechanisms. We administered a long-acting nifedipine formulation (controlled release (CR) nifedipine: 20 mg/day) to hypertensive patients for 6 months. There were no other changes of drug treatment during therapy with CR nifedipine. Clinical and biochemical data obtained before and after CR nifedipine administration were compared. All markers were measured by enzyme-linked immunosorbant assay. The levels of soluble markers (soluble CD40 ligand, soluble P-selectin, and soluble E-selectin), microparticles (MP) (platelet-derived MP, monocyte-derived MP, and endothelial cell-derived MP), and adiponectin differed between the control group and the hypertension group. The levels of these markers were also different in hypertensive patients with and without type 2 diabetes compared with the control group. In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment. In contrast, markers were unchanged in the hypertensive patients without type 2 diabetes. Adiponectin was increased after 6 months of CR nifedipine treatment in hypertensive patients with type 2 diabetes. The effects of CR nifedipine on platelet/monocyte activation and adiponectin levels demonstrated in the present study indicate the potential effectiveness of calcium antagonist therapy for hypertensive patients with type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Studies with angiographic endpoints [2][3][4]7,8] have shown that medical therapy can attenuate the rate of lesion development and/or reduce existing lesions. However, most angiographic studies have had too small a sample size to detect a reduction in morbidity or mortality associated with the measured changes in coronary artery diameter.…”

Section: Discussionmentioning

confidence: 99%

“…For the angiographic analyses the incidence of progression in the placebo treatment group was assumed to be 0.45 (45% of patients in the placebo treatment group demonstrating "progression"--however defined--over a 3-year period) [3,4,7,8,[34][35][36][37][38][39][40]. Thus, for a test with 80% power at a two-sided 5% significance level to detect a 30% reduction (to 0.315) in the quinapril treatment group, 203 patients are required per treatment group.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention

Texter¹,

Lees

Pitt

et al. 1993

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Summary. The rationale, trial design, and statistical aspects of QUIET, the QUinapril Ischemic Event Trial, are described. QUIET is a prospective, double-blind placebocontrolled study that will assess the ability of the angiotensin-converting enzyme (ACE) inhibitor quinapril to reduce the rate of cardiac ischemic events and to slow or prevent the development of coronary artery atherosclerosis as assessed by serial angiography in a normolipidemic population without left ventricular dysfunction. The study began in September 1991 and has completed recruitment with 1740 patients across 38 centers (28 U.S., 4 Canada, 6 Europe) by the end of 1992. Patients are randomized to 20 mg of quinapril or placebo once daily and continue in the study for 3 years. Study completion is projected for 1995.

show abstract

“…Meta-analysis by Furberg et al showed that nifedipine is associated with dose related increase in mortality in patients with CAD, a study which included patients with acute coronary syndromes (ACS) (Furberg et al, 1995). However, the only trial included in the meta-analysis that involved patients with stable angina was the International Nifedipine trial on Antiatherosclerotic Therapy (INTACT), which showed that patients on nifedipine had retardation of atherosclerotic disease by angiogram, though clinical symptoms were not reported (Lichtlen et al, 1990). A Coronary Disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system (ACTION) study reported that, in patients with stable angina and hypertension, long-acting nifedipine was acceptably safe (no increased incidence of myocardial infarction, heart failure or death), but there was no evidence of improvement in mortality or other major cardiac endpoints and no reduction in refractory angina in already maximally medically treated patients (Poole-Wilson et al, 2004;Sierra & Coca, 2008).…”

Section: Clinical Applicationmentioning

confidence: 99%

Therapy for Angina Pectoris Secondary to Coronary Disease

Innasimuthu¹,

Kumar²,

Gao³

et al. 2011

Angina Pectoris

View full text Add to dashboard Cite

Retardation of angiographic progression of coronary artery disease by nifedipine

Cited by 572 publications

References 21 publications

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention

Therapy for Angina Pectoris Secondary to Coronary Disease

Contact Info

Product

Resources

About